New class of molecules play key role in influencing the immune system

August 24, 2016
Proresolving lipid mediators – resolvin D1 (RvD1), resolvin D2 (RvD2), and maresin 1 (MaR1) – modulate T cell responses. Credit: Valerio Chiurchiu et al., Science Translational Medicine (2016)

In a study published online this week in Science Translational Medicine, investigators from Brigham and Women's Hospital and the Santa Lucia Foundation in Rome report that resolvins and maresins, molecules produced in the body naturally from certain omega-3 fatty acids, regulate subsets of white blood cells that play a central role in inflammation and the immune system. The new findings suggest that resolvins and maresins are part of a new class of molecules that may be useful for treating chronic inflammatory and autoimmune diseases.

Resolvins and maresins, first discovered by Charles N. Serhan, PhD, director of the Center for Experimental Therapeutics and Reperfusion Injury at BWH, are critical to terminate and resolve acute inflammation. Uncontrolled inflammation or failure to resolve inflammation can lead to several chronic inflammatory and autoimmune diseases.

In the newly published work, the team examined the roles of two resolvins and one maresin in human blood lymphocytes, finding that they reduced the activation and prevented the differentiation of two types of pathogenic , Th1 and Th17 cells. The team also found that these molecules could regulate Treg cells, a separate subset of cells that can tamp down the immune response. The team further verified these results in a mouse model deficient in these molecules. Together, these discoveries suggest that pro-resolving lipid mediators influence the balance between pathogenic Th1/Th17 and tolerogenic Treg cells, a balance that is typically altered during chronic inflammatory and .

The team proposes that these pro-resolving lipid mediators may prove effective as potent anti-inflammatories by targeting those key cells responsible for triggering chronic inflammation or autoimmunity.

"It is now widely appreciated that uncontrolled inflammation is integral to many human diseases including neurodegenerative diseases, cardiovascular diseases as well as ," said Serhan. "The results of this study now provide the ground work to appreciate the role of resolvins, and potentially other novel pro-resolving mediators, in the immune system. Armed with the results of this collaboration, we and other investigators can now consider new treatments and therapeutic strategies for translating these findings with pro-resolving mediators to human health and many diseases."

Explore further: What foods can help fight the risk of chronic inflammation?

More information: "Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses," Science Translational Medicine, stm.sciencemag.org/lookup/doi/ … scitranslmed.aaf7483

Related Stories

What foods can help fight the risk of chronic inflammation?

May 16, 2016
A new study by the University of Liverpool's Institute of Ageing and Chronic Disease has identified food stuffs that can help prevent chronic inflammation that contributes to many leading causes of death.

Aspirin and omega-3 fatty acids work together to fight inflammation

February 21, 2013
Experts tout the health benefits of low-dose aspirin and omega-3 fatty acids found in foods like flax seeds and salmon, but the detailed mechanisms involved in their effects are not fully known. Now researchers reporting ...

Novel lipid mediators may play role in omega-3 PUFA effects

June 25, 2016
(HealthDay)—Novel lipid mediators may be involved in the beneficial effects associated with omega-3 polyunsaturated fatty acids (PUFAs) in obesity, according to a study published online June 16 in Diabetes.

How to engineer a stronger immune system

August 9, 2016
With a trick of engineering, scientists at the Gladstone Institutes improved a potential weapon against inflammation and autoimmune disorders. Their work could one day benefit patients who suffer from inflammatory bowel disease ...

Potential therapeutic targets identified for multiple sclerosis

January 25, 2016
Treatment of multiple sclerosis (MS) and other inflammatory diseases may benefit by new findings from a study that identified potential therapeutic targets for a devastating disease striking some 2.3 million people worldwide.

Bio-molecules in human breast milk stop inflammation

October 14, 2015
Human breast milk, which provides essential nutrients and antibodies to newborns, has long been known to play an important role in infant development and the immune system. In a new study published in Mucosal Immunology, ...

Recommended for you

Drug could cut transplant rejection

November 21, 2017
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs, according to new research by Queen Mary University of London ...

Atopic eczema—one size does not fit all

November 21, 2017
Researchers from the UK and Netherlands have identified five distinct subgroups of eczema, a finding that helps explain how the condition can affect people at different stages of their lives.

Study explores whole-body immunity

November 21, 2017
Over the next few months, millions of people will receive vaccinations in the hope of staving off the flu—and the fever, pain, and congestion that come with it.

Breast milk found to protect against food allergy

November 20, 2017
Eating allergenic foods during pregnancy can protect your child from food allergies, especially if you breastfeed, suggests new research from Boston Children's Hospital. The study, published online today in the Journal of ...

Zika-related nerve damage caused by immune response to the virus

November 20, 2017
The immune system's response to the Zika virus, rather than the virus itself, may be responsible for nerve-related complications of infection, according to a Yale study. This insight could lead to new ways of treating patients ...

How a poorly explored immune cell may impact cancer immunity and immunotherapy

November 17, 2017
The immune cells that are trained to fight off the body's invaders can become defective. It's what allows cancer to develop. So most research has targeted these co-called effector T-cells.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.